These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 20113411

  • 1. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension.
    Backonja MM, Malan TP, Vanhove GF, Tobias JK, C102/106 Study Group.
    Pain Med; 2010 Apr; 11(4):600-8. PubMed ID: 20113411
    [Abstract] [Full Text] [Related]

  • 2. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study.
    Backonja M, Wallace MS, Blonsky ER, Cutler BJ, Malan P, Rauck R, Tobias J, NGX-4010 C116 Study Group.
    Lancet Neurol; 2008 Dec; 7(12):1106-12. PubMed ID: 18977178
    [Abstract] [Full Text] [Related]

  • 3. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain.
    Simpson DM, Gazda S, Brown S, Webster LR, Lu SP, Tobias JK, Vanhove GF, NGX-4010 C118 Study Group.
    J Pain Symptom Manage; 2010 Jun; 39(6):1053-64. PubMed ID: 20538187
    [Abstract] [Full Text] [Related]

  • 4. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia.
    Irving G, Backonja M, Rauck R, Webster LR, Tobias JK, Vanhove GF.
    Clin J Pain; 2012 Feb; 28(2):101-7. PubMed ID: 21753727
    [Abstract] [Full Text] [Related]

  • 5. A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia.
    Webster LR, Malan TP, Tuchman MM, Mollen MD, Tobias JK, Vanhove GF.
    J Pain; 2010 Oct; 11(10):972-82. PubMed ID: 20655809
    [Abstract] [Full Text] [Related]

  • 6. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia.
    Irving GA, Backonja MM, Dunteman E, Blonsky ER, Vanhove GF, Lu SP, Tobias J, NGX-4010 C117 Study Group.
    Pain Med; 2011 Jan; 12(1):99-109. PubMed ID: 21087403
    [Abstract] [Full Text] [Related]

  • 7. Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia.
    Webster LR, Tark M, Rauck R, Tobias JK, Vanhove GF.
    BMC Neurol; 2010 Oct 11; 10():92. PubMed ID: 20937130
    [Abstract] [Full Text] [Related]

  • 8. NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study.
    Simpson DM, Brown S, Tobias JK, Vanhove GF, NGX-4010 C107 Study Group.
    Clin J Pain; 2014 Feb 11; 30(2):134-42. PubMed ID: 23446088
    [Abstract] [Full Text] [Related]

  • 9. An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy.
    Simpson DM, Estanislao L, Brown SJ, Sampson J.
    J Pain Symptom Manage; 2008 Mar 11; 35(3):299-306. PubMed ID: 17959343
    [Abstract] [Full Text] [Related]

  • 10. Capsaicin 8% topical patch (Qutenza)--a review of the evidence.
    Jones VM, Moore KA, Peterson DM.
    J Pain Palliat Care Pharmacother; 2011 Mar 11; 25(1):32-41. PubMed ID: 21426216
    [Abstract] [Full Text] [Related]

  • 11. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia.
    Watson CP, Tyler KL, Bickers DR, Millikan LE, Smith S, Coleman E.
    Clin Ther; 1993 Mar 11; 15(3):510-26. PubMed ID: 8364943
    [Abstract] [Full Text] [Related]

  • 12. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy.
    Simpson DM, Brown S, Tobias J, NGX-4010 C107 Study Group.
    Neurology; 2008 Jun 10; 70(24):2305-13. PubMed ID: 18541884
    [Abstract] [Full Text] [Related]

  • 13. Qutenza®: a capsaicin 8% patch for the management of postherpetic neuralgia.
    Wallace M, Pappagallo M.
    Expert Rev Neurother; 2011 Jan 10; 11(1):15-27. PubMed ID: 21158551
    [Abstract] [Full Text] [Related]

  • 14. NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain.
    Noto C, Pappagallo M, Szallasi A.
    Curr Opin Investig Drugs; 2009 Jul 10; 10(7):702-10. PubMed ID: 19579176
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain.
    Babbar S, Marier JF, Mouksassi MS, Beliveau M, Vanhove GF, Chanda S, Bley K.
    Ther Drug Monit; 2009 Aug 10; 31(4):502-10. PubMed ID: 19494795
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 10; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 17. Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain.
    Webster LR, Peppin JF, Murphy FT, Lu B, Tobias JK, Vanhove GF.
    Diabetes Res Clin Pract; 2011 Aug 10; 93(2):187-197. PubMed ID: 21612836
    [Abstract] [Full Text] [Related]

  • 18. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R, Lorenz V, Korak-Leiter M, Kager I, Sittl R.
    Clin Ther; 2007 Aug 10; 29(8):1591-606. PubMed ID: 17919542
    [Abstract] [Full Text] [Related]

  • 19. Diclofenac potassium liquid-filled soft gelatin capsules in the management of patients with postbunionectomy pain: a Phase III, multicenter, randomized, double-blind, placebo-controlled study conducted over 5 days.
    Riff DS, Duckor S, Gottlieb I, Diamond E, Soulier S, Raymond G, Boesing SE.
    Clin Ther; 2009 Oct 10; 31(10):2072-85. PubMed ID: 19922878
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study.
    Mankowski C, Poole CD, Ernault E, Thomas R, Berni E, Currie CJ, Treadwell C, Calvo JI, Plastira C, Zafeiropoulou E, Odeyemi I.
    BMC Neurol; 2017 Apr 21; 17(1):80. PubMed ID: 28431564
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.